— Affimed NV (NASDAQ: AFMD) reported Q3 2019 loss of EUR0.17 per share, vs. EUR0.19 reported last year.
— Revenues were EUR2.1 million, vs. EUR0.3 million reported last year.
— Research & development expenses were EUR11.7 million compared to EUR9.8 million last year.
— Cash, cash equivalents and current financial assets totaled EUR76.5 million as of September 30, 2019.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
BIIB Earnings: Biogen Q1 2024 adj. earnings rise despite lower revenues
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Wednesday reported an increase in adjusted profit for the first quarter of 2024, despite a decline in revenues. Total revenue declined 7% year-over-year to
Hasbro (HAS) Q1 2024 Earnings: Key financials and quarterly highlights
Hasbro, Inc. (NASDAQ: HAS) reported first quarter 2024 earnings results today. Revenues decreased 24% year-over-year to $757.3 million. Net earnings attributable to Hasbro, Inc. were $58.2 million, or $0.42 per
BA Earnings: Highlights of Boeing’s Q1 2024 financial results
The Boeing Company (NYSE: BA) on Wednesday announced financial results for the first quarter of 2024, reporting a narrower net loss, on an adjusted basis. Revenues dropped 8%. Core loss,
